Tipifarnib in Subjects With Myelodysplastic Syndromes
Status:
Terminated
Trial end date:
2020-01-24
Target enrollment:
Participant gender:
Summary
This a Phase 2 randomized, open-label, two-stage study designed to investigate the antitumor
activity of tipifarnib in approximately 36 eligible subjects with MDS who have no known
curative treatment. Subjects will be randomized to receive tipifarnib orally with food
according to one of 2 treatment regimens.